Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Albireo AB has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are handled by 5 distinct examiners across 4 distinct art units. O DELL, DAVID K is the busiest examiner, with 1 pending office action currently assigned. The portfolio shows that each of the 5 pending office actions is assigned to a different individual, creating a one-to-one ratio of actions to distinct examiners.
These examiners are located within 4 distinct art units, indicating a slight concentration of the technology within specific USPTO divisions. Because the busiest examiner, O DELL, DAVID K, only has 1 pending office action, there is no single point of contact for the majority of the portfolio. This distribution requires a strategy that addresses the unique requirements of 5 different examiners across the Biotechnology & Pharmaceuticals sector. Practitioners must manage these varied examination styles independently, as there is no significant overlap to provide a unified prosecution path. The focus across 4 art units suggests a diverse range of pharmaceutical applications under review.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 3 (60%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
| PALENIK, JEFFREY T | 1 | 53.5% | +27.0% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18207996 | TREATING HEPATITIS | SZNAIDMAN, MARCOS L | 53d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18138375 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | BARSKY, JARED | 33d |
| 18207996 | TREATING HEPATITIS | SZNAIDMAN, MARCOS L | 53d |
| 18896264 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | O DELL, DAVID K | — |
| 18778225 | Crystal Modifications of Odevixibat | COLEMAN, BRENDA LIBBY | — |
| 18501402 | Treating Alagille Syndrome (ALGS) | PALENIK, JEFFREY T | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1621 | 1 |
| 1624 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18896264 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | O DELL, DAVID K | 1621 | DP | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18778225 | Crystal Modifications of Odevixibat | COLEMAN, BRENDA LIBBY | 1624 | §112DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18501402 | Treating Alagille Syndrome (ALGS) | PALENIK, JEFFREY T | 1615 | §103DP | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18207996 | TREATING HEPATITIS | SZNAIDMAN, MARCOS L | 1628 | §102§103Other | Non-Final OA | 53d | Pending | Jun 09, 2023 |
| 18138375 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | BARSKY, JARED | 1628 | §103DP | Non-Final OA | 33d | Pending | Apr 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlbireo AB has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
David K O Dell has the most, with 1 of Albireo AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
